Hemodialysis Catheter Antimicrobial Coating Patents 2026
Hemodialysis Catheter Antimicrobial Coating Patents 2026
Catheter-related bloodstream infections carry mortality risks 26-fold higher than the general population. This report maps the patent and clinical evidence behind antimicrobial surface coatings designed to prevent them.
Antimicrobial Coatings for Hemodialysis Catheters: A 2026 Landscape
Hemodialysis central venous catheters remain in use for 25–33% of prevalent hemodialysis patients at any given time, with catheter-related bloodstream infection (CRBSI) incidence ranging from approximately 1.5 to 3.7 infections per 1,000 catheter-days across studies retrieved in this dataset. Gram-positive organisms—predominantly coagulase-negative staphylococci and Staphylococcus aureus including MRSA—account for 60–70% of positive cultures.
Biofilm formation on catheter surfaces is identified across multiple sources as the central pathogenic mechanism driving treatment resistance, recurrent bacteremia, and catheter failure. The technology response spans four distinct sub-domains: surface coatings chemically bonded or impregnated into catheter polymer matrices; antimicrobial lock solutions instilled between dialysis sessions; antimicrobial catheter caps protecting the hub; and antiseptic dressings at the insertion site.
The field demonstrates a clear three-phase maturation arc in this dataset. Foundational work from 2004–2012 established feasibility of chlorhexidine/silver sulfadiazine and bismuth-film coatings. Mid-stage clinical validation from 2013–2020 produced network meta-analyses confirming CRBSI reduction (RR 0.70, 95% CI 0.53–0.91 across 23 studies). The most recent phase (2021–2026) is characterized by multi-component coatings, novel drug-releasing matrices, and photodynamic antimicrobial approaches.
In this dataset, 4 patents were identified with assignee and jurisdiction data spanning US, EP, and IN jurisdictions. Innovation is distributed across academic institutions, individual inventors, European SMEs, and South Asian technical institutes in retrieved records. No large medical device corporations appear explicitly as patent assignees in this dataset, though 3M and Teleflex/Arrow are implicated through clinical product evaluations.
Filing Activity and Clinical Evidence by Technology Approach
The dataset spans patent filings from 2012 to 2026 and clinical literature from 2004 to 2023. Both streams reveal a field moving from single-agent inorganic coatings toward multi-component organic and nanoparticle systems with documented clinical validation.
Patent Assignees by Jurisdiction and Status — Retrieved Records
In this dataset, US and EP jurisdictions each contribute 2 patent records, with India contributing 1 pending filing; no single jurisdiction dominates the retrieved patent landscape.
↗ Click bars to exploreClinical Evidence Timeline by Technology Cluster — 2004–2023
In this dataset, the mid-stage development period (2013–2020) contains the highest density of clinical evidence records, with organic antimicrobial coatings and lock solutions each generating multiple validated studies during this window.
↗ Click bars to exploreKey Clinical Settings and Research Populations for Antimicrobial Catheter Coatings
Retrieved sources span four principal clinical application domains, from primary hemodialysis access to adjacent ICU, urinary catheter, and neurosurgical EVD settings, each contributing distinct evidence for antimicrobial coating efficacy.
Hemodialysis CVC — Primary Domain
Approximately 60% of retrieved sources focus directly on hemodialysis catheter infection, with CRBSI incidence of 1.5–3.7 per 1,000 catheter-days documented across studies from India, Iran, Palestine, Somalia, Pakistan, Dubai, and China. Gram-positive organisms account for 60–70% of positive cultures, validating the scale of unmet need driving coating technology development. A 2023 systematic review pooled 13 studies and 46,139 patients to confirm antimicrobial lock solution superiority over heparin-only controls.
Hemodialysis AccessICU / Critical Care CVC Settings
A 2004 prospective randomized study in ICU populations confirmed reduced colonization in double-lumen CVCs impregnated with chlorhexidine/silver sulfadiazine. The 2018 network meta-analysis across 23 studies—drawing from mixed ICU and hemodialysis populations—confirmed CRBSI risk reduction (RR 0.70, p=0.008). Tegaderm CHG (3M) received NICE Medical Technology Guidance in 2015, primarily driven by ICU evidence.
Critical CareUrinary Catheter Coating Cross-Over
Multiple retrieved results address urinary catheter coatings providing coating science relevant to vascular access: zinc oxide nanoparticle/amylase coatings (2021), diamond-like carbon coatings (2021), cyanobacterial polymer coatings (2020), and silver nanoparticle antifouling coatings (2018). Anti-adhesion and anti-biofilm mechanisms validated in urinary catheter models directly inform parallel hemodialysis catheter development. A multi-center India trial of noble metal alloy coating for urinary catheters provides large-scale clinical safety data applicable to the vascular access field.
Urological DevicesNeurosurgical EVD Catheter Coatings
A 2010 study evaluated EVD catheter antimicrobial impregnation with triclosan, trimethoprim, and rifampicin, demonstrating efficacy against MRSA and multi-resistant gram-negative organisms. A 2013 meta-analysis of antimicrobial EVD catheters found a 3.6% infection rate with antimicrobial coating versus 13.7% with standard catheters, with a statistically significant odds ratio. These cross-domain results provide strong parallel evidence supporting the efficacy of antimicrobial impregnation strategies applicable to hemodialysis catheter engineering.
Neurosurgical DevicesKey Patent Assignees in Hemodialysis Catheter Antimicrobial Coatings (Retrieved Records)
In this dataset, 4 named patent assignees were identified across US, EP, and IN jurisdictions, with filing dates spanning 2012 to 2026. Innovation in retrieved records is distributed across academic institutions, individual inventors, European SMEs, and South Asian technical institutes rather than concentrated in large medical device corporations.
Patent Filings per Assignee — Hemodialysis Catheter Antimicrobial Coatings (Dataset Snapshot)
↗ Click bars to exploreEUROCHIT Danuta Kruszewska
EUROCHIT holds 2 active EP patents filed in 2012 and 2016 covering a nanocoating of biocompatible polymers incorporating extracellular metabolites from Lactobacillus reuteri DAN080. The polymer forms a water-active gel layer functioning as a physical-biological barrier against bacterial colonization. Both patents are listed as active in retrieved records, reflecting sustained commercial and IP investment in probiotic-derived surface functionalization.
European Patent Office — EPBrown University
Brown University holds 1 active US patent (2020) for polyurethane catheter coatings releasing auranofin, an FDA-approved gold compound that disrupts bacterial thioredoxin reductase. In vitro testing demonstrated full inhibition of MRSA biofilm formation for 8–26 days, exceeding the typical 14-day efficacy ceiling of prior antimicrobial catheter coatings. The patent is listed as active in retrieved records.
United States — USFive Directional Signals in Hemodialysis Catheter Antimicrobial Coating (2020–2026)
The most recent filings and publications in this dataset (2020–2026) reveal five distinct directional signals, ranging from multi-component biofilm-disrupting gel coatings to repurposed FDA-approved drug matrices and non-chemical physical disinfection strategies.
Multi-Component Biofilm-Disrupting Coatings
The KIT REH-Gel patent (IN, pending, 2026) combines three mechanistically distinct agents: rhamnolipid (a biosurfactant disrupting bacterial membrane adhesion), EDTA (a chelating agent destabilizing gram-negative outer membranes and biofilm matrix), and hyaluronic acid (a mucoadhesive polymer providing sustained contact and physical barrier). This multi-target approach directly addresses resistance evolution concerns associated with single-agent coatings. It represents the most recent filed innovation in this dataset.
Repurposed Drug Coatings Exceeding the 14-Day Efficacy Ceiling
The Brown University auranofin patent (US, active, 2020) demonstrates that repurposing FDA-approved drugs with novel mechanisms—specifically gold-thiol chemistry of auranofin disrupting bacterial thioredoxin reductase—can overcome the 14-day efficacy limit of established coatings. Full inhibition of MRSA biofilm was reported in vitro for up to 26 days, which exceeds the typical efficacy benchmark for prior antimicrobial catheter coatings. This positions auranofin as a candidate for hemodialysis-specific tunneled catheter use cases requiring multi-week dwell efficacy.
Surface Coatings vs. Antimicrobial Lock Solutions: Key Dimensions
Click any row to explore further.
| Dimension | Surface Coatings (Impregnated / Nanocoating) | Antimicrobial Lock Solutions |
|---|---|---|
| Mechanism | Antimicrobial agents released from or bound to catheter polymer surface; inhibit extraluminal and surface biofilm | Antimicrobial agents instilled into catheter lumen between dialysis sessions; target intraluminal colonization |
| Efficacy Duration | Typically up to 14 days for standard coatings; Brown University auranofin coating demonstrated 8–26 days MRSA inhibition in vitro | Efficacy dependent on dwell time per session; taurolidine-citrate and EDTA evaluated in RCTs for tunneled hemodialysis catheters |
| Clinical Evidence | 2018 network meta-analysis (23 studies): RR 0.70 (95% CI 0.53–0.91) for CRBSI reduction with antimicrobial-coated CVCs | 2023 systematic review (13 studies, 46,139 patients): antimicrobial locks significantly reduce CRBSI vs. heparin-only controls |
| Colonization Route Addressed | Extraluminal skin flora migration; surface biofilm formation | Intraluminal hub contamination; intraluminal biofilm |
| Representative Agents | Chlorhexidine/silver sulfadiazine; auranofin-polyurethane; Lactobacillus reuteri metabolites; rhamnolipid/EDTA/HA (REH-Gel) | Taurolidine-citrate (TauroLock); tetrasodium EDTA; heparin combinations; citrate-based formulations |
| Resistance Risk | Single-agent coatings risk resistance selection with elution; multi-component approaches (REH-Gel, auranofin) designed to mitigate | Taurolidine and EDTA have low resistance potential; antibiotic locks (e.g. vancomycin) carry resistance selection risk |
| IP Landscape (Dataset) | Active patents: EUROCHIT EP (2012, 2016), Brown University US (2020), KIT IN pending (2026) | No patents identified in this dataset; evidence base is clinical literature only (2018–2023) |
| Combined Regimen Evidence | Combined regimens (lock + coated catheter) remain understudied in hemodialysis-specific populations per this dataset | Combined regimens (lock + coated catheter) remain understudied in hemodialysis-specific populations per this dataset |
Frequently Asked Questions: Hemodialysis Catheter Antimicrobial Coatings
Gram-positive organisms—predominantly coagulase-negative staphylococci and Staphylococcus aureus including MRSA—are reported as the dominant pathogens, accounting for 60–70% of positive cultures across multiple studies retrieved in this dataset.
A 2018 network meta-analysis across 23 studies confirmed that antimicrobial-impregnated CVCs reduce CRBSI rates compared to standard CVCs, with a relative risk of 0.70 (95% CI 0.53–0.91, p=0.008). A 2004 prospective randomized ICU study also confirmed reduced colonization in double-lumen CVCs impregnated with chlorhexidine and silver sulfadiazine.
The Brown University US patent (active, 2020) describes polyurethane coatings releasing auranofin—an FDA-approved gold compound—that fully inhibited MRSA biofilm formation in vitro for 8–26 days. This exceeds the typical 14-day efficacy ceiling of prior antimicrobial catheter coatings, which is particularly relevant for tunneled hemodialysis catheters intended for months of use.
REH-Gel is an anti-biofilm catheter coating formulation developed by KIT-Kalaignar Karunanidhi Institute of Technology in India, with a patent filed in 2026 (status: pending). It combines three agents: rhamnolipid (a biosurfactant), EDTA (a chelating agent), and hyaluronic acid (a mucoadhesive polymer), targeting biofilm prevention through synergistic disruption of bacterial adhesion mechanisms.
A 2023 systematic review pooling 13 studies and 46,139 hemodialysis patients confirmed that antimicrobial locking solutions significantly reduce CRBSI versus heparin-only controls. Taurolidine-citrate locks were specifically evaluated in a 2020 double-blind RCT in Iranian hemodialysis patients, and tetrasodium EDTA was identified as effective against gram-positive, gram-negative, and fungal biofilms in a 2018 Canadian hospital study.
In this dataset, active patents are held by EUROCHIT Danuta Kruszewska (EP, 2012 and 2016, nanocoating with Lactobacillus reuteri metabolites) and Brown University (US, 2020, auranofin-releasing polyurethane). A pending patent is held by KIT-Kalaignar Karunanidhi Institute of Technology (IN, 2026, REH-Gel). The MAXEY UVC catheter system patent (US, 2020) is listed as inactive in retrieved records.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.